Scientific Publications by FDA Staff
Cytokine 2008 Feb;41(2):182-6
The IP10 (CXCL10) specific cDNA probe of the mCK-5c multiprobe RNase protection assay kit carries two nucleotide insertions that complicate the interpretation of results.
Sauder C, Pedras-Vasconcelos J, Puig M, Verthelyi D
Sauder, C (reprint author), Ctr Biol Evaluat & Res, Off Vaccines Res & Review, Div Viral Prod, Bldg 29A,Room 2C-20,HFM460,8800 Rockville Pike, Bethesda, MD 20892 USA Ctr Biol Evaluat & Res, Off Vaccines Res & Review, Div Viral Prod, Bethesda, MD 20892 USA US FDA, Div Therapeut Prot, Off Biotechnol Prod, CDER, Bethesda, MD 20892 USA
RNase protection assays (RPA) employing multiprobe sets are powerful tools to simultaneously measure transcription of several different genes. We used BD Biosciences/Pharmingen's mouse chemokine probeset mCK-5c to measure chemokine gene expression in brain and spleen tissue of mice. Depending on the RPA protocol used, we observed differences in the relative amounts of transcripts for interferon-inducible protein 10 (IP-10) and T-cell activation-3 (TCA-3). Isolation and sequencing of the IP-10 specific gene from the mCK-5c probeset revealed two nucleotide insertions in the probe that are not present in the natural IP-10 cDNA. We show that these insertions cause RNase A-dependent degradation of the protected IP-10 mRNA yielding a fragment indistinguishable in size from that specific for TCA-3, thus leading to over-interpretation of TCA-3 expression as well as underestimation of IP-10 gene expression levels.
|Category: Journal Article|
|PubMed ID: #18226543|
|Includes FDA Authors from Scientific Area(s): Biologics Drugs|
|Entry Created: 2011-10-04||Entry Last Modified: 2015-06-03|